Please assess the completion status of the following clinical trial:

Trial Title: PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent prior to admission to this study~2. Women, age \> 18 years~3. Histologically confirmed breast cancer~4. Metastatic or locally recurrent disease; locally recurrent disease must not be amenable to resection with curative intent (patients who are considered suitable for surgical or ablative techniques following potential down-staging with study treatment are not eligible)~5. Patient must have~   * At least one lesion, not previously irradiated, that can be measured accurately at baseline as ≥ 10mm in the longest diameter (except lymph nodes which must have short axis ≥15mm) with CT, or magnetic resonance imaging (MRI) which is suitable for accurate repeated measurements, OR~  * lytic or mixed bone lesions in the absence of measurable disease as defined above; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible.~6. Radiological or clinical evidence of recurrence or progression~7. Triple-negative disease~8. Formalin fixed paraffin embedded tumour sample from the primary or recurrent cancer must be available for central testing~9. Patients must be able to swallow and retain oral medication~10. Haematologic and biochemical indices within protocol specified ranges~11. ECOG performance status 0-2~12. Non-childbearing potential. If patient is of childbearing potential, she must have a negative serum pregnancy test and agree to use adequate contraception~13. Willing and able to provide written informed consent~Exclusion Criteria:~1. Patients with confirm brain metastases or a history of primary central nervous system tumours or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases.~2. Prior chemotherapy for metastatic breast cancer~3. Radiotherapy with a wide field of radiation within 4 weeks before the first dose of study medication~4. Prior treatment with PI3K inhibitors, AKT inhibitors or mTOR inhibitors~5. Prior treatment with paclitaxel or docetaxel in the (neo)adjuvant setting within 12 months from inclusion into this study~6. Pre-existing sensory or motor polyneuropathy ≥ Grade 2 according to CTCAE~7. Malabsorption syndrome or other condition that would interfere with enteral absorption~8. Clinically significant pulmonary dysfunction~9. Prolongation defined as a QTc interval \>470msecs or other significant abnormalities in rhythm, conduction or morphology of resting ECG including 2nd degree (Type II) or 3rd degree AV block or bradycardia (ventricular rate \<50 beats/min)~10. Any factors that increase risk of QTc prolongation or risk of arrythmic events~11. Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure NYHA Grade ≥2, or cardiac ejection fraction outside institutional range of normal or \<50%~12. Clinically significant abnormalities of glucose metabolism~13. Patients with proteinuria or creatine \>1.5xULN concurrent with creatinine clearance \<50mL/min~14. Exposure to potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2D6 within 2 weeks before the first dose of study treatment~15. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study entry~16. Psychological, familial, sociological or geographical conditions that do not permit compliance with the study protocol.~17. Detained persons or prisoners~18. Pregnant or nursing women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel + AZD5363 (Type: ACTIVE_COMPARATOR): Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Capivasertib 400 mg was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
- Paclitaxel + Placebo (Type: PLACEBO_COMPARATOR): Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Placebo was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).